Omni Health Inc (OMHE)

[lesgetrich]

Just repeating debunked claims doesn't prove anything...

Omni Post # 16580 Debunking Your Claims

Omni Post # 16591 - Debunked again

ROTFLMAO Generally Accepted Accounting Principles (GAAP) are not creative accounting. Your fake accounting is.

Antidilutive - Definition

Antidilutive is a term describing the effects of securities retirement, securities conversion or corporate actions...

...A transaction is considered to be antidilutive if its effect is to increase the amount of EPS, either by lowering the share count or increasing earnings.

This is the opposite of a dilutive transaction which causes dilution of your shares. The reduction in OS announced last week was an antidilutive transaction...

Omni Health, Inc. Converts 62% (600 Million Common Shares) of Company Common Stock into Preferred Stock in a Capitalization Restructuring

Andrey Soloviev, the company's Chief Executive Officer and Chairman of the Board has converted 556,890,449 shares of common stock into 5,600,000 Series A Preferred Stock. In addition, 50,000,000 shares of common stock are to be converted into 5,000,000 shares of Series B Preferred Stock by several large shareholders. The actions reduce the outstanding common stock of OMHE by 62% to 368,938,292 shares of common stock.

Mr. Soloviev stated, "Recognizing the continued evolution of our anti-aging cream business, and our strategy to grow and enter into the cannabis and biotech platforms, we conducted a thorough review of our corporate structure to optimize our support of both existing and future operations." He went on to say, "This conversion of common stock to preferred stock benefits our shareholders. This allows our shareholders the ability to look into the future without concern of dilution from these shares being available to be sold into the market."

975,828,741 Outstanding Shares (OS) of common stock before restructuring

368,938,292 Outstanding Shares (OS) of common stock after restructuring.


606,890,449 shares - 62% of OS taken out of circulation.

Based on their pro forma statement in the most recent 10-Q showing earnings of $593,858 thru first 9 months minus the effect of the VitaCig sale and assuming zero earnings in 4FQ17...

New Earnings per Share (EPS) with $593,858 earnings and 368,938,741 OS = $.0016/share

Old EPS with $593,858 earnings and 975,828,741 OS = $.0006/share

New Price Earnings Ratio (PE) at $.0016 EPS and $.0232 pps ($.0232/$.0016) = 14.5x

Old PE at $.0006 EPS and $.0232 pps ($.0232/$.0006) = 38.66x

At the same PE as before the restructuring, OMHE common shares should now be re-valued at 38.66 x $.0016 or $.0618/share at the current pps

The restructuring hasn't been processed yet. We're still showing an OS of 975,828,741 on the exchanges. Once the restructuring is completed OMHE will be extremely undervalued before we even hear anything new about the company and it's plans.

NUMBERS DON'T LIE